Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin plus flucloxacillin versus vancomycin alone for MRSA bacteraemia
ACTRN12610000940077Phase 2Completed
- Sponsor
- Dr Joshua Davis
- Start
- Jan 2011
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Staphylococcal bacteremia comparing Vancomycin plus flucloxacillin with Vancomycin alone (2 arms). Primary endpoint: Duration of MRSA bacteraemia. Started Jan 2011; status: completed.
02
Drugs
vancomycinflucloxacillin
03
Conditions
Staphylococcal bacteremia
Beyond the preview
Go deeper on ACTRN12610000940077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000940077.